Targeted therapy

• MEK inhibitors
  10 June 2016

  Members
  trametinib
  cobimetinib
  MEK162
  AZD6244
  RO5126766
  GDC-0623
  PD0325901
  See also
  RAS-ERK pathway inhibitors RAF inhibitors MEK inhibitors ERK inhibitors
  References
  http://www.nature.com/nrd/journal/v13/n12/fig_tab/nrd4281_T1.html

• BCL2 inhibitors
  18 May 2016

  Examples
  venetoclax venetoclax is a BH3-mimetic and acts as a Bcl-2 inhibitor. It blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2, BCL2 ) protein, leading to programmed cell death of CLL cells.

• IL-17 inhibitors
  10 May 2016

  Examples
  ixekizumab
  braodalumab

• HSP90 inhibitors
  2 May 2016

  hsp90 inhibitors WP
  An Hsp90 inhibitor is a substance that inhibits that activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies.
  Furthermore a number of Hsp90 inhibitors are currently undergoing clinical trials for a variety of cancers.
  Hsp90 inhibitors include the natural products geldanamycin and radicicol as well as (...)

• immune checkpoint inhibitors
  2 November 2014

  immune checkpoint blockade; immune checkpoint inhibitors; immune checkpoint inhibition; PD-L1 inhibitor; PD-1 inhibitor; PD-L1 inhibitors; immune blockade ; immune checkpoint blockers
  Examples
  atezolizumab (Yervoy)
  nivolumab (Opdivo)
  pembrolizumab (Keytruda)
  atezolizumab (Tecentriq)
  ipilimumab
  pidilizumab
  durvalumab
  Images
  https://twitter.com/MedicalAbacus/status/849353365582696448
  A ligand-receptor interaction that has been investigated as a target for cancer (...)

• PARP inhibitors
  6 November 2012

  PARP inhibitor WKP
  Definition : PARP is a protein that is involved in DNA repair. PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP). They are developed for multiple indications; the most important is the treatment of cancer.
  Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy.
  In addition to their use in cancer therapy, PARP inhibitors are considered a (...)

• EGFR inhibitors
  2 April 2012

  References
  Quantitative Proteomic profiling identifies protein correlates to EGFR kinase inhibition. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash SM, Agus DB, Mallick P. Mol Cancer Ther. 2012 Mar 21. PMID: #22411897#

• KIT inhibitors
  2 April 2012

  c-Kit inhibitors
  Oncogenic mutations leading to persistent kinase activities are associated with malignancies. Therefore, deciphering the signaling networks downstream these oncogenic stimuli remains a challenge to gather insights into targeted therapy.
  Resistance to Kit inhibitors
  Cell survival is driven by the Kit/Shp2/Ras/Mek/Erk1/2 pathway whereas G1/S transition during cell-cycle is accelerated by both the Kit/Stat5 and Kit/PI3K/Akt pathways.
  The combined use of clinically relevant (...)

• RANKL inhibitors
  2 January 2012

  anti-RANKL drugs
  Types
  denosumab (Prolia, Xgeva)
  See also
  targeted therapy

• BRAF inhibitors
  2 January 2012

  anti-BRAF drugs
  Types
  vemurafenib (PLX4032)
  See also
  targeted therapy

0 | 10 | 20